~ Sep 07 Life-Saving Cancer Drugs Rejected by the FDA - References

References

1. Available at: www.cancer.org/docroot/stt/stt_0.asp. Accessed June 11, 2007.

2. Available at: www.docguide.com/news/content.nsf/news. Accessed June 11, 2007.

3. Mor G, Fu HH, Alvero AB. Phenoxodiol, a novel approach for the treatment of ovarian cancer. Curr Opin/Investig Drugs. 2006 Jun;7(6):542-8.

4. Kamsteeg M, Rutherford T, Sapi E, et al. Phenoxodiol--an isoflavone analog—induced apoptosis in chemoresistant ovarian cancer cells. Oncogene. 2003 May 1;22(17):2611-20.

5. de Souza PL, Liauw W, Links M, Pirabhahar S, Kelly G, Howes LG. Phase I and pharmacokinetic study of weekly NV06 (Phenoxodiol), a novel isoflav-3-ene, in patients with advanced cancer. Cancer Chemother & Pharmacol. 2006 Oct;58(4):427-33.

6. Available at: www.marshalledwardsinc.com/index04.cfm?section=04&status=1&id=124. Accessed June 11, 2007.

7. Gamble JR, Xia P, Hahn CN, et al. Phenoxodiol, an experimental anticancer drug, shows potent antiangiogenic properties in addition to its antitumor effects. Int J Cancer. 2006 May 15;118(10):2412-20.

8. Available at: www.marshalledwardsinc.com/index04.cfm?section=04&status=1&id=165.Accessed June 11, 2007.

9. Alvero AB, Brown D, Montagna M, Matthews M, Mor G. Phenoxodiol-Topotecan Co-Administration Exhibit Significant Anti-Tumor Activity Without Major Adverse Side Effects. Cancer Biol Ther. 2007 Apr. 19;6(4). [Epub ahead of print]

10. Available at: www.marshalledwardsinc.com/index04.cfm?section=04&status=1&id=211.Accessed June 11, 2007.

11. Available at: http://clinicaltrials.gov/ct/show/NCT00382811?order=1. Accessed June 11, 2007.

12. Available at: www.newswise.com/articles/view/516230/. Accessed June 11, 2007.

13. Available at: www.hrpca.org/phenoxodiol.htm. Accessed June 11, 2007.

14. Kluger HM, McCarthy MM, Alvero AB, et al. The X-linked inhibition of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. J Transl Med. 2007 Jan 26;5:6.

15. Available at: www.marshalledwardsinc.com/index.cfm?section=03&subsec=0316#10. Accessed June 11, 2007.

16. Available at: http://online.wsj.com/article/SB117911315709601659.html?mod=article-outset-box. Accessed June 11, 2007.

17. Available at: http://ir.idm-biotech.com/phoenix.zhtml?c=193146&p=irol-newsArticle&ID=759764&highlight=. Accessed June 11, 2007.

18. Available at: http://www.pharmalive.com/News/index.cfm%3Farticleid%3D440765. Accessed June 11, 2007.

19. Available at: http://cancer.iu.edu/osteosarcoma/index.php. Accessed June 11, 2007.

20. Available at: www.nci.nih.gov/cancertopics/pdq/treatment/osteosarcoma/patient/allpages/print. Accessed June 11, 2007.

21. Available at: http://www.drugs.com/nda/junovan_061026.html.Accessed June 11, 2007.

22. Available at: http://en.wikipedia.org/wiki/Macrophage. Accessed June 11, 2007.

23. Available at: www.drugs.com/nda/junovan_070509.html. Accessed June 11, 2007.

24. Kleinerman ES, Murray JL, Snyder JS, Cunningham JE, Fidler IJ. Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Res. 1989 Aug 15;49(16):4665-70.

25. Available at: http://cancer.iu.edu/osteosarcoma/patients/stories/cindi/php. Accessed June 11, 2007.

26. Available at: www.drugs.com/nda/junovan_070403.html. Accessed June 11, 2007.

27. Available at: http://cancer.iu.edu/osteosarcoma/patients/timeline/index.php. Accessed June 11, 2007.

28. Available at: http://cancer.iu.edu/osteosarcoma/patients/intreatment/chemotherapy/. Accessed June 11, 2007.

29. Strum SB, Pogliano D. A Primer on Prostate Cancer, The Empowered Patient's Guide. 2nd ed. Hollywood, FL: The Life Extension Foundation; 2005.

30. Available at: http://online.wsj.com/article/SB117824324837591781.html. Accessed May 22, 2007.

31. Available at: http://www.genta.com/genta/Products/genasense.html. Accessed May 25, 2007.

32. Raynaud FI, Orr RM, Goddard PM, et al. Pharmocokinetics of G3139, a phosphorothioate oligodeoxyneucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther. 1997 Apr;281(1):420-7.

33. Cotter, FE. Antisense therapy of hematologic malignancies. Semin Hematol. Oct;36(4 Suppl 6):9-14.

34. Available at: http://genta.com/Genta/InvestorRelation/2007/press_20070214.html. Accessed May 31, 2007.

35. O'Brien S, Moore JO, Boyd TE, et al. Randomized Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Sodium (Bcl-2 antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol. 2007; 0:JCO. 2006.07.1191v1.

36. Available at: www.genta.com/Genta/InvestorRelation/2006/press_20060301.html. Accessed June 4, 2007.

37. Available at: http://www.drugs.com/nda/torisel_061096.html. Accessed May 30, 2007.

38. Available at: http://www.thejournalnews.com/apps/pbcs.dll/article?AID=/20070325/BUSINESS01/703250307/1066&template=printart. Accessed June 12, 2007.

40. Available at: http://news.morningstar com/news/ printNews.asp?id=/News/DJ/200705161321DOWJONESDJONLINE000845_univ.xml. Accessed June 12. 2007.

41. Available at: http://www.wyeth.com/news?nav=display&navTo=/wyeth_html/home/news/pressreleases/2007/1180576865144.html. Accessed June 12, 2007.

42. Available at: http://www.geron.com/showpage.asp?code=prodcatv. Accessed June 12. 2007.

43. Available at: www.curetoday.com/backissues/v3n3/departments/specialreport/. Accessed June 12, 2007.

44. Available at: http://www.fda.gov/ohrms/dockets/AC/05/slides/2005-4095S1_01_05-AdvMag-Barentsz.ppt#755,1. Accessed June 12, 2007.

45. Available at: http://www.cancer.org/docroot/CRI/content/CRI_2_6x_photodynamic_therapy.asp?sitearea=. Accessed June 12, 2007.

46. Available at: http://www.nytimes.com/2005/01/08/business/08drug.html?ex=1262926800&en=850b1ce92db6387b&ei=5088&partner=rssnyt.

Accessed June 12, 2007.

47. Available at: http://psa-rising.com/med/research/atrasentan-Xinlay-asco05.htm. Accessed June 12, 2007.

48. Available at: http://www.hrpca.org/atrasentan.htm. Accessed June 12, 2007.

49. Available at: http://www.nytimes.com/2007/06/04/health/04drug.html?ex=1181793600&en=8aadd4d94116b406&ei=

5070. Accessed June 12, 2007.

50. Available at: http://psa-rising.com/blog/index.php/2007/06/02/washington-dc-june-

4th-prostate-cancer-walk. Accessed June 12, 2007.

51. Available at: http://psa-rising.com/blog/index.php/2007/06/. Accessed June 12, 2007.

52. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006 Jul 1;24(19):3089-94.

53. Available at: http://professional. cancerconsultants.com/oncology_main_news.aspx?id=38681. Accessed July 5, 2007.

54. Beinart G, Rini BI, Weinberg V, Small EJ. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin Prostate Cancer. 2005 Jun 4;4(1):55-60.

55. Available at: http://www.aacrmeetingabstracts.org/cgi/content/abstract/2004/1/1028-a?maxtoshow=&HITS=10&hits=10&RESULTFORMAT= 1&author1=rutherford&andorexacttitle=and&titleabstract=phenoxodiol&andorexacttitleabs= and&searchid=1&FIRSTINDEX=0&sortspec=relevance&tdate=12/31/2005&resourcetype=HWCIT. Accessed July 5, 2007.

56. Available at: http://www.aacrmeeting abstracts.org/cgi/content/abstract/2006/2/A27?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=1&author1=morre&andorexacttitle= and&titleabstract=tNOX&andorexacttitleabs=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT. Accessed July 5, 2007.

57. Available at: http://www.marshalledwardsinc.com/index04.cfm?section=04&status=1&id=163. Accessed July 5, 2007.

58. Romet-Lemonne JL, Mills B, Fridman WH, Munsel M. Prospectively planned analysis of data from a phase III study of liposomal muramyltripeptide phosphatidylethano lamine in the treatment of osteosarcoma. J Clin Oncol. 2005 Sept 10;23(26):6437-8.

59. Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006 Oct 10;24(29):4738-45.

60. Nelson JB, Carducci MA, Zonnenberg B, et al. The endothelin-A receptor antagonist atrasentan improves time to clinical progression in hormone refractory prostate cancer patients: a randomized, double-blind, multi-national study. J Urol. 2001;165:168A.

61. Available at: http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d?vgnextoid= 76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=40&abstractID=33839. Accessed July 5, 2007.

62. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005 Nov 1;23(31):7794-803.

63. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinicallyoccult lymph-node metastases in prostatecancer. N Engl J Med. 2003 Jun19;348(25):2491-9.


Free Shipping in the Continental U.S. on Orders over $50
The statements made here have not been evaluated by the FDA. The foregoing statements are based upon sound and reliable studies, and are meant for informational purposes. Consult with your medical practitioner to determine the underlying cause of your symptoms. Please always check your purchase for possible allergins and correct dosage on the bottle before use.

While we work to ensure that product information is correct, on occasion manufacturers may alter their ingredient lists. Actual product packaging and materials may contain more and/or different information than that shown on our Web site. We recommend that you do not solely rely on the information presented and that you always read labels, warnings, and directions before using or consuming a product. For additional information about a product, please contact the manufacturer. Content on this site is for reference purposes and is not intended to substitute for advice given by a physician, pharmacist, or other licensed health-care professional. You should not use this information as self-diagnosis or for treating a health problem or disease. Contact your health-care provider immediately if you suspect that you have a medical problem. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease or health condition. Life Ex Online assumes no liability for inaccuracies or misstatements about products.